Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 dose-escalation study of INT-787 in healthy subjects
NL-OMON52038Phase 1Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of INT-787 in chronic liver disease (CLD) (15 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Safety and tolerability after single ascending doses, Safety and tolerability after multiple ascending doses and 1 more. Started Jun 2021; status: completed.
02
Drugs
INT-787
03
Conditions
chronic liver disease (CLD)
Beyond the preview
Go deeper on NL-OMON52038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52038.